GLENMARK LIFE SCIENCES
|
|
BOM : 543322     NSE : GLS     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : NA |
Nov 26,2024 |
Price(EOD): ₹ 1,066.70
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 13,067.08 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
GLENMARK LIFE SCIENCES | -1.6% | 2.6% | 74.8% |
SUN PHARMACEUTICAL INDUSTRIES | -0.9% | -4.8% | 50.2% |
CIPLA | 1.5% | 0.1% | 19.9% |
DR REDDYS LABORATORIES | -0.4% | -8.2% | 7.1% |
ZYDUS LIFESCIENCES | 0.6% | -5.3% | 51% |
DIVIS LABORATORIES | 3% | 5.9% | 65% |
MANKIND PHARMA | 0.6% | 3.1% | 34.4% |
TORRENT PHARMACEUTICALS | 4.3% | -2.7% | 54.2% |
LUPIN | -0.1% | -4.4% | 72.4% |
FUNDAMENTAL ANALYSIS OF GLENMARK LIFE SCIENCES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GLENMARK LIFE SCIENCES
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
30.86
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 423.50 Cr
[Latest Qtr - Sep2024 - Standalone Results ] 5.63
P/B Calculated based on Book Value of Rs 2,321.26 Cr
[Latest Year - Mar2024 - Standalone Results ] 5.93
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
174% 164% 140% |
SHARE PRICE MOMENTUM OF GLENMARK LIFE SCIENCES
GLENMARK LIFE SCIENCES vs SENSEX
DEBT OF GLENMARK LIFE SCIENCES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0 0 - |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF GLENMARK LIFE SCIENCES
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF GLENMARK LIFE SCIENCES
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-13.89% -15.75% -15.16% -14.5% |
-14.86% -19.59% -19.8% -19.73% |
QtrlyTrend |
-8 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
GLENMARK LIFE SCIENCES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | 3.7% | -0.2% | 35.7% |
S&P BSE MIDSMALLCAP | 3.6% | -0.5% | 36.5% |
S&P BSE HEALTHCARE | 2.4% | 1% | 45.8% |
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY500 MULTICAP 50:25:25 | 3.3% | -1.1% | 30.1% |
You may also like the below Video Courses
FAQ about GLENMARK LIFE SCIENCES
Is GLENMARK LIFE SCIENCES good for long term investment?
As on Nov 26,2024, the Fundamentals of GLENMARK LIFE SCIENCES look Strong and hence it may be good for long term investment! See Financial Performance of GLENMARK LIFE SCIENCES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GLENMARK LIFE SCIENCES UnderValued or OverValued?
As on Nov 26,2024, GLENMARK LIFE SCIENCES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GLENMARK LIFE SCIENCES ?
As on Nov 26,2024, the Intrinsic Value of GLENMARK LIFE SCIENCES is Rs. 403.36 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 389.81
Fair Value [Median EV / Sales Model] : Rs. 403.36
Fair Value [Median Price / Sales Model] : Rs. 444.30
Estimated Median Fair Value of GLENMARK LIFE SCIENCES : Rs. 403.36
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.